LCN2 and obesity disorder: Meanwhile, an increase in serum levels of lipocalin-2 has been suggested as a useful biomarker with which to determine clinical responses to antihistamine treatment in CSU patients: this biomarker has also been shown to be correlated with metabolic syndrome and obesity [11, 31].